DCR

metastatic/advanced - colorectal cancer (mCRC) metastatic/advanced - colorectal cancer (mCRC)

versus Standard of Care (SoC)
atezolizumab plus cometinib vs. Standard of Care (SoC) 1 -
atezolizumab plus SoC vs. Standard of Care (SoC) 1 -

mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)

versus Bevacizumab plus FOLFOXIRI
atezolizumab plus FOLFOXIRI plus bevacizumab vs. Bevacizumab plus FOLFOXIRI 1 -

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus capecitabine
atezolizumab plus bevacizumab vs. capecitabine 1 -
versus regorafenib
atezolizumab alone vs. regorafenib 1 -
atezolizumab plus cometinib vs. regorafenib 1 -